How Long Does Peptide Therapy Take to Work? A Protocol-by-Protocol Timeline

"How long until I see results?" is one of the most common questions patients ask when starting telehealth peptide therapy. It is also one of the most frequently misanswered — either with unrealistic optimism or with a vague "it varies by patient" that doesn't give patients enough to plan around.

The honest answer is: it depends on the protocol, because GLP-1 receptor agonist therapy, sermorelin, and NAD+ subcutaneous protocols produce effects through different mechanisms on different timescales. This article gives protocol-by-protocol timelines grounded in what the clinical evidence and consistent patient experience actually show.

What it does not do is promise specific outcomes or guarantee timelines. Individual variation is real. What is presented here is the clinical pattern — what typically happens, what the milestone windows look like, and what it means when a patient's experience is outside the typical pattern.

GLP-1 receptor agonist therapy: the timeline

GLP-1 receptor agonists — prescribed as compounded semaglutide or tirzepatide — work primarily through central and peripheral satiety signaling and slowed gastric emptying. The result is reduced caloric intake that drives weight loss over time. The timeline has distinct phases.

Weeks 1–4: titration and first effects

Most patients notice reduced appetite within the first one to two weeks of GLP-1 administration. Meals feel satisfying at lower volumes. Food preoccupation decreases. Some patients describe the effect as the mental "food noise" quieting down.

On the scale, measurable weight change typically begins in weeks two through four. The early rate of loss is often faster than it will be at later stages — the combination of strong initial appetite suppression and a patient starting from a higher caloric intake baseline creates a relatively large initial deficit.

Side effects are most common in this window. Nausea, mild gastrointestinal discomfort, and reduced energy are the most frequently reported early symptoms. For most patients these are transient, peaking in the first two to four weeks and resolving as the body adapts to the medication. For patients with persistent or significant side effects, the prescriber evaluates whether dose adjustment is appropriate.

What patients often misunderstand in this window: The absence of strong nausea does not mean the medication is not working. Some patients experience minimal side effects and robust appetite suppression simultaneously. Side effects are not a marker of efficacy.

Weeks 4–12: active loss phase

This is typically the most visibly productive window for GLP-1 therapy. The titration phase — if the protocol involves titration — is usually completing during weeks 4 to 12, and patients are reaching their prescribed therapeutic dose. Appetite suppression is consistent, caloric deficit is established, and weight loss is occurring at the fastest sustained rate it will reach.

Body composition changes become visible to the patient during this window. Clothing fits differently. Energy on physical activity improves as excess metabolic load decreases. Lab markers — fasting glucose, HbA1c, lipids — begin improving in patients where those were elevated at baseline.

Common patient question at this stage: "Why is my loss slowing down compared to the first month?" The initial loss window includes a significant water weight and glycogen-store reduction component on top of fat loss. As the protocol continues, the loss composition shifts toward predominantly fat mass, which produces slower scale movement at equivalent caloric deficit.

Months 3–6: adaptation and first plateau window

The period from months three through six is where the GLP-1 weight loss plateau commonly occurs for the first time. Metabolic adaptation — the body's adjustment of resting energy expenditure to match the new lower body weight — catches up with the caloric deficit, and loss slows or stalls temporarily.

This is a normal part of the clinical arc, not a sign of failure or medication inefficacy. The prescriber's management at this stage typically involves evaluating whether a dose adjustment, behavioral modification, or watchful waiting is appropriate.

Patients who work through this adaptation window — through a combination of dose management and behavioral recalibration — typically resume a slower but sustained loss trajectory.

Months 6–12 and beyond

The twelve-month clinical picture for GLP-1 therapy shows continued metabolic improvement even when scale weight progress has slowed. Cardiometabolic markers continue improving. Body composition — particularly visceral fat reduction — continues even when total body weight has plateaued. The long-term benefit of the protocol is not captured by the weight curve alone.

The 12-month GLP-1 patient journey guide covers this arc in fuller detail.

---

Sermorelin: the timeline

Sermorelin's mechanism is fundamentally different from GLP-1. It does not suppress appetite or change gastric emptying. It stimulates the pituitary to produce endogenous growth hormone through the body's own feedback axis — the GHRH axis. The effects accrue gradually, which means the timeline is longer and more progressive than GLP-1 therapy.

Weeks 1–4: adaptation phase

The first month of sermorelin therapy produces minimal effects that patients consciously notice. Growth hormone stimulation is occurring at the physiologic level — pulsatile GH secretion, primarily during slow-wave sleep, is being supported — but the downstream effects of that stimulation on body composition and recovery are not yet measurable on the surface.

Some patients report subtle sleep quality changes beginning in the first two to four weeks — a sense of sleeping more deeply, waking more rested. This is often the earliest patient-experienced signal. Others report nothing consciously different until later.

What patients often misunderstand in this window: The absence of noticeable effects in week one does not mean sermorelin is not working. The mechanism is gradual. Expecting immediate effects like the appetite changes GLP-1 produces will produce disappointment with a medication that is actually performing as intended.

Months 1–3: first functional effects

Between months one and three, the most consistently reported early functional effect is improved sleep quality and recovery. Patients describe feeling more recovered after training, sleeping more deeply, and experiencing improved mood and energy during waking hours.

These effects are not yet body composition changes — they are the functional upstream effects of improved GH-axis signaling. Body composition changes at the scale and measurement level are not typically meaningful in this window for most patients.

Patients who are consistent with the protocol and who train with resistance exercise are better positioned to see early body composition effects than patients who are sedentary, because the body composition effects of GH-axis support are amplified by the anabolic stimulus of resistance training.

Months 3–6: body composition effects begin

The window from month three through month six is where body composition effects typically become measurable for patients on sermorelin who are consistent with the protocol. Lean mass improvements are gradual — patients may notice changes in how their body looks and feels before the scale registers meaningful change.

Fat mass reduction in this window is modest but directionally consistent. The mechanism is not appetite suppression — it is the metabolic effect of physiologically appropriate GH on lipolysis and lean mass support. The rate is slower than GLP-1 therapy, the trajectory is more gradual, and the clinical framing is endocrine optimization rather than weight management.

Months 6–12: accumulated benefit

The cumulative benefit of sermorelin therapy becomes most apparent at the six-month to twelve-month mark. Patients who have been consistent with the protocol and who incorporate resistance training report the most significant body composition improvements in this window.

Sleep quality, recovery, and energy effects that began earlier have typically become the new baseline by this point — patients often forget what their sleep felt like before the protocol began.

Sermorelin is a long-duration protocol. Its benefit is not in a six-week transformation — it is in the sustained support of a physiologic axis that otherwise declines with age. For more detail on dosing, timing, and the clinical structure, see the sermorelin dosing and timing article.

---

NAD+ subcutaneous protocols: the timeline

NAD+ therapy operates through a different mechanism entirely: increasing intracellular NAD+ availability in tissues with high metabolic demand. The timeline reflects that mechanism — some effects are rapid because they depend on immediate cellular availability, while others are gradual because they involve downstream processes that accumulate over time.

Weeks 1–3: energy and cognitive effects

Most patients on NAD+ subcutaneous protocols report the earliest effects within the first one to three weeks of consistent administration. These early effects typically fall into two categories:

Energy. Improved perceived energy — particularly in the afternoon and evening periods where energy typically flags — is the most commonly reported early NAD+ effect. Patients describe this as more consistent energy across the day rather than dramatic peaks.

Cognitive clarity. Improved mental clarity, reduced cognitive fatigue, and faster recovery from mentally demanding tasks are frequently reported in the first two to four weeks. These effects reflect NAD+'s role in the mitochondrial electron transport chain in neurons and in the processes that clear cellular metabolic byproducts.

What patients often misunderstand in this window: The energy and cognitive effects of NAD+ therapy are not equivalent to the acute energy boost of caffeine or stimulants. They are more subtle — a baseline elevation in cellular function that patients notice especially in the absence of their usual energy flags. Patients looking for a dramatic acute effect may not recognize the benefit when it arrives.

Weeks 4–12: stabilization of functional effects

By weeks four through twelve, the energy and cognitive effects that began in the early window have typically stabilized at a new baseline. Patients who were inconsistent with administration often notice the difference on days they miss a dose.

In this window, patients pursuing NAD+ for training recovery or physical performance begin to see clearer recovery effects — reduced post-training soreness duration, faster perceived recovery between sessions. These effects reflect NAD+'s role in the DNA repair pathways activated during exercise-induced cellular stress.

The NAD+ for performance article covers the athletic recovery framing in more detail. The cellular energy restoration article covers the broader mechanism.

Months 3–12: longer-term cellular effects

The longer-term effects of NAD+ therapy — improvements in inflammatory regulation, cellular senescence burden, and mitochondrial density — accumulate over months of consistent use. These effects are not directly perceptible the way energy and cognitive effects are. They are measurable through lab markers (including NAD+ blood levels, inflammatory markers, and metabolic panels at follow-up) rather than through subjective experience.

Patients who pursue NAD+ therapy for longevity-oriented goals should understand that the most clinically meaningful long-term effects are in this category — and that discontinuing therapy after the first few months because visible changes have plateaued means stopping the protocol before the accumulating cellular effects have had time to develop.

---

General principles that apply across all protocols

Regardless of which protocol a patient is on, a few principles govern the timeline:

Consistency beats intensity. The protocols described here require consistent administration over weeks and months to produce their full effect. Missing doses, storing medication incorrectly, or inconsistent injection technique reduces effective drug delivery and extends the timeline to results.

Adjunct behaviors matter. Resistance training amplifies sermorelin's body composition effects. Adequate protein intake preserves lean mass during GLP-1 therapy. Sleep consistency amplifies both sermorelin's GH-axis effects and NAD+'s recovery benefits. The medication is one variable in a clinical picture that includes lifestyle.

Short-term impatience creates long-term distortion. Patients who escalate doses independently, discontinue protocols prematurely, or switch protocols before reaching the assessment window are the most common source of the "peptide therapy didn't work" narrative. Most of those cases involve protocols that were not given the minimum required time or dose to produce their clinical effect.

The 90-day assessment is a benchmark, not an endpoint. Ninety days is a clinically meaningful checkpoint for evaluating whether the protocol is producing expected effects. It is not the finish line. For GLP-1, it is roughly the transition from the active titration phase to the steady-state management phase. For sermorelin, it is the beginning of measurable body composition effects. For NAD+, it is solidly within the stabilized functional-effects window.

For program options, see the programs index. For a cost breakdown by protocol, see the telehealth peptides cost article. TelePeptide serves patients in 48 US states + DC (excludes AK and MS).

---

Compounded peptide preparations are not FDA-approved as finished drug products. Clinical services provided by MD Integrations, P.C. — a contracted medical group operating a multi-state network of licensed physicians, NPs, and PAs. Available in 48 US states + DC (excludes AK and MS). Not medical advice. Individual results vary. Timelines described are typical patterns based on clinical observation and available literature; individual patient outcomes depend on clinical factors evaluated by the prescribing clinician.